Danaher backs away from Catalent as CDMO struggles with productivity problems: report

Catalent’s fresh problems with costs and productivity may have hurt its prospects for an M&A deal.

Life sciences conglomerate Danaher has ditched a plan to pursue an acquisition of Catalent, Bloomberg reports. The publication first reported back in February that Danaher was interested in buying the CDMO at a “significant premium.”